Stella Jones press release ( STLJF ): Q1 Non-GAAP EPS of C$1.12. Revenue of C$791M (+2.3% Y/Y). More on Stella-Jones Inc. Stella-Jones Inc. (SJ:CA) Q4 2025 Earnings Call Transcript Stella-Jones Inc. 2025 Q4 - Results - Earnings Call Presentation Historical earnings data for Stella-Jones Inc. Dividend scorecard for Stella-Jones Inc. Financial information for Stella-Jones Inc.
Stella Jones press release ( STLJF ): Q1 Non-GAAP EPS of C$1.12. Revenue of C$791M (+2.3% Y/Y). More on Stella-Jones Inc. Stella-Jones Inc. (SJ:CA) Q4 2025 Earnings Call Transcript Stella-Jones Inc. 2025 Q4 - Results - Earnings Call Presentation Historical earnings data for Stella-Jones Inc. Dividend scorecard for Stella-Jones Inc. Financial information for Stella-Jones Inc.
Lucky Strike Entertainment press release ( LUCK ): Q3 Net income of $16.9 million versus prior year net income of $13.3 million Revenue of $342.2M (+0.7% Y/Y) misses by $11.15M . Same Store Revenue increased 0.2% versus the prior year Adjusted EBITDA of $109.0 million versus $117.3 million in the prior year Year to date capital expenditures of $90.1 million versus $117.5 million in the prior year ...
Lucky Strike Entertainment press release ( LUCK ): Q3 Net income of $16.9 million versus prior year net income of $13.3 million Revenue of $342.2M (+0.7% Y/Y) misses by $11.15M . Same Store Revenue increased 0.2% versus the prior year Adjusted EBITDA of $109.0 million versus $117.3 million in the prior year Year to date capital expenditures of $90.1 million versus $117.5 million in the prior year From December 29, 2025 through May 6, 2026, we acquired one water park. Total locations in operation as of May 6, 2026 is 368 More on Lucky Strike Entertainment Lucky Strike: Confirmation Of The Volatility And Downside J.P. Morgan cuts Lucky Strike Entertainment to sell on weak traffic, EBITDA erosion Seeking Alpha’s Quant Rating on Lucky Strike Entertainment Historical earnings data for Lucky Strike Entertainment Dividend scorecard for Lucky Strike Entertainment
908 Devices press release ( MASS ): Q1 GAAP EPS of -$0.32 misses by $0.10 . Revenue of $13.38M (+13.6% Y/Y) beats by $0.22M . Recurring revenue was $4.0 million, representing 30% of total revenues for the quarter Adjusted gross margin was 57% for the first quarter of 2026. Ended the quarter with a strong balance sheet, with a cash position of $111.7 million, consuming less than $1.5 million in the...
908 Devices press release ( MASS ): Q1 GAAP EPS of -$0.32 misses by $0.10 . Revenue of $13.38M (+13.6% Y/Y) beats by $0.22M . Recurring revenue was $4.0 million, representing 30% of total revenues for the quarter Adjusted gross margin was 57% for the first quarter of 2026. Ended the quarter with a strong balance sheet, with a cash position of $111.7 million, consuming less than $1.5 million in the first quarter. 2026 Guidance 908 Devices now expects full year 2026 revenues to be in the range of $67.0 million to $70.0 million (prior $64.5 million to $67.5 million) vs. $65.94M consensus , representing 19% to 25% growth compared to 2025 revenue. More on 908 Devices 908 Devices Inc. (MASS) Q4 2025 Earnings Call Transcript 908 Devices beats top-line and bottom-line estimates; introduces FY26 outlook Seeking Alpha’s Quant Rating on 908 Devices Historical earnings data for 908 Devices Financial information for 908 Devices
Schroptschop/iStock via Getty Images Recap From My First Coverage This isn’t my first time covering Cameco Corporation ( CCJ ); in fact, I did so back in late January of this year. Since then a lot has come out and a lot has happened. We’ve seen commodities surge as a result of the escalating conflicts in the Middle East. Company-wise, CCJ has also released a new earnings report showing that long-...
Schroptschop/iStock via Getty Images Recap From My First Coverage This isn’t my first time covering Cameco Corporation ( CCJ ); in fact, I did so back in late January of this year. Since then a lot has come out and a lot has happened. We’ve seen commodities surge as a result of the escalating conflicts in the Middle East. Company-wise, CCJ has also released a new earnings report showing that long-term pricing for uranium is picking up speed in terms of pricing. Rising from $80/lb back in June of 2025 to now $91.5/lb. First Coverage (Seeking Alpha) buying a $54 billion company, which is up 168% on a 12-month period, I think opens up risk. I’ll admit that the growth in the next few years should be very strong, thanks to one of the main investments CCJ has Part of the reason for me rating CCJ a hold initially was the stretched valuation I thought it had. It seems the market has caught up as well, seeing as shares are now down some 14% since then. It’s difficult rating any stock a Hold, I think. Partly because for CCJ the underlying business is incredibly strong and there is lasting long-term growth here. But on the contrary, the valuation does not provide a lot of downside protection, at least back then. For me, the long-term outlook always wins, and for CCJ, it looks very positive, which is why I wouldn't rate it a Sell previously. What has changed now is that CCJ has come down in price; the report that came out showed strong figures, especially with Westinghouse now being an even more integral part of CCJ. It’s rare that I upgrade a rating so close to having started covering, but I think here all the boxes I need for a Buy rating are ticked. Business Model And Recent Earnings Report CCJ is not just a mining company, driving revenues and earnings from having the price of uranium rise. think of CCJ as a vertically integrated company that has both the upstream, midstream, and downstream as part of its operations. It controls the entire value chain from exploration to re...
rafal_olechowski Shares of MannKind Corporation ( MNKD ) added ~16% in the premarket on Wednesday after the company announced plans for a new jointly developed therapy as part of an expanded license and collaboration agreement with United Therapeutics ( UTHR ). The biotech company from Danbury, Connecticut, stated that it has been working on a new treatment, a dry powder inhaler version of the dru...
rafal_olechowski Shares of MannKind Corporation ( MNKD ) added ~16% in the premarket on Wednesday after the company announced plans for a new jointly developed therapy as part of an expanded license and collaboration agreement with United Therapeutics ( UTHR ). The biotech company from Danbury, Connecticut, stated that it has been working on a new treatment, a dry powder inhaler version of the drug ralinepag (MNKD-1501), for United Therapeutics ( UTHR ) as part of the expanded agreement. Under a 2018 agreement, MannKind ( MNKD ) and United Therapeutics ( UTHR ) currently market a dry powder formulation of the lung disease therapy treprostinil, as Tyvaso DPI, for conditions including pulmonary arterial hypertension. MannKind ( MNKD ) said that under the expanded deal, it received $5M from UTHR last month aimed at supporting the expedited development of ralinepag DPI, which is set to be initially commercialized for pulmonary arterial hypertension. The company is also entitled to $35M in development milestones and 10% royalties on net sales of MNKD-1501 while United ( UTHR ) seeks to develop the drug for additional lung disorders such as interstitial lung disease and idiopathic pulmonary fibrosis. However, United Therapeutics ( UTHR ) trended lower in the premarket on Wednesday after its Q1 2026 results failed to meet Street forecasts. MannKind ( MNKD ) is scheduled to report its Q1 results after the close on Wednesday. More on MannKind, United Therapeutics United Therapeutics: The Future Lies With Manufactured Organs United Therapeutics: Maintaining 'Strong Buy' On Second TETON Study Program Win MannKind: Strategic Uncertainty Follows United Therapeutics' Pivot (Rating Downgrade) MannKind Q1 2026 Earnings Preview United Therapeutics Q1 2026 Earnings Preview
Investors should scoop up shares of Davita as demand for the company's treatments picks up, according to Deutsche Bank. The bank upgraded the dialysis service provider to buy from hold. Is also raised its price target to $220 from $126, implying 40% upside from Tuesday's close. Davita reported better-than-expected earnings for the first quarter on Tuesday, sending shares nearly 6% higher in off-ho...
Investors should scoop up shares of Davita as demand for the company's treatments picks up, according to Deutsche Bank. The bank upgraded the dialysis service provider to buy from hold. Is also raised its price target to $220 from $126, implying 40% upside from Tuesday's close. Davita reported better-than-expected earnings for the first quarter on Tuesday, sending shares nearly 6% higher in off-hours trading. DVA 5D mountain DVA rises "The two shining stars of the quarter were: (1) Revenue per treatment; (2) Treatment growth," analyst Pito Chickering said Tuesday in a note to clients. "At this point, we are unable to sit on the sidelines." Treatments came in 10 basis points above analysts' consensus estimate for the first quarter, according to Deutsche Bank. The company also said it expects demand for treatments to increase by between 20 and 50 basis points for the current year. Davita's revenue per treatment was $417.59 for the period, topping the Street's expectation of $8.30. That marks a 4.4% increase in treatment revenue on a year-over-year basis. "There are still a lot of variables like new starts/ mortality which can impact these numbers. Bears are playing for treatment growth structurally impacted by both SGLT2 inhibitors plus GLP-1 impacts, but with treatment growth moving up for the first time in years, we believe these headwinds simply aren't coming in as bears hoped for," Chickering wrote. Deutsche Bank's call goes against consensus on the Street. Of the 10 analysts covering DaVita, 6 have a hold on the stock, LSEG data shows. Shares have risen 38% in the year to date.
(RTTNews) - NRG Energy, Inc. (NRG), an energy and home services company, Wednesday reported lower earnings for the first quarter compared to the same period last year, despite higher revenues.
(RTTNews) - NRG Energy, Inc. (NRG), an energy and home services company, Wednesday reported lower earnings for the first quarter compared to the same period last year, despite higher revenues.
Recent developments in the AI chip sector underscore a significant surge in demand for high-performance computing solutions, particularly for AI infrastructure. AMD's latest financial results reveal robust growth in their Data Center segment, attributed to increasing demand for their AI-optimized processors and GPUs. Expansions in global compute infrastructure, marked by strategic collaborations w...
Recent developments in the AI chip sector underscore a significant surge in demand for high-performance computing solutions, particularly for AI infrastructure. AMD's latest financial results reveal robust growth in their Data Center segment, attributed to increasing demand for their AI-optimized processors and GPUs. Expansions in global compute infrastructure, marked by strategic collaborations with industry giants such as Meta, AWS, and Google Cloud, highlight the broader industry trend of...
Britain's 'special relationship' with the United States may be under renewed scrutiny, but when it comes to football, it appears to be in fine health, writes Dan Roan.
Britain's 'special relationship' with the United States may be under renewed scrutiny, but when it comes to football, it appears to be in fine health, writes Dan Roan.